Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency-Reference-Cited by-同舟云学术

Mitapivat: A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

Published:2024-02 Issue:6 Volume:31 Page:683-687
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

De Surya K.¹²

Affiliation:

1. Department of Chemistry, Conju-Probe, San Diego, California, USA

2. Bharath University, Chennai, Tamil Nadu, 600126, India

Abstract

Abstract: Mitapivat is an orally bioavailable small molecule allosteric activator of pyruvate kinase. It was approved by the US FDA on February 17, 2022, and the European Union in November 2022 for the treatment of hemolytic anemia in adult patients with pyruvate kinase deficiency. In this short perspective, physicochemical properties, synthesis, dosage and administration, mechanism of action, pharmacodynamics, pharmacokinetics, drug interactions, and adverse reactions of mitapivat are described.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference17 articles.

1. Koralkova P.; van Solinge W.W.; van Wijk R.; Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis. Int J Lab Hematol 2014,36(3),388-397

2. Kanno H.; Fujii H.; Miwa S.; Structural analysis of human pyruvate kinase L-gene and identification of the promoter activity in erythroid cells. Biochem Biophys Res Commun 1992,188(2),516-523

3. Secrest M.H.; Storm M.; Carrington C.; Casso D.; Gilroy K.; Pladson L.; Boscoe A.N.; Prevalence of pyruvate kinase deficiency: A systematic literature review. Eur J Haematol 2020,105(2),173-184

4. Bianchi P.; Fermo E.; Lezon-Geyda K.; Beers E.J.; Morton H.D.; Barcellini W.; Glader B.; Chonat S.; Ravindranath Y.; Newburger P.E.; Kollmar N.; Despotovic J.M.; Verhovsek M.; Sharma M.; Kwiatkowski J.L.; Kuo K.H.M.; Wlodarski M.W.; Yaish H.M.; Holzhauer S.; Wang H.; Kunz J.; Addonizio K.; Al-Sayegh H.; London W.B.; Andres O.; Wijk R.; Gallagher P.G.; Grace R.F.F.; Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. Am J Hematol 2020,95(5),472-482

5. Rab M.A.E.; Van Oirschot B.A.; Kosinski P.A.; Hixon J.; Johnson K.; Chubukov V.; Dang L.; Pasterkamp G.; Van Straaten S.; Van Solinge W.W.; Van Beers E.J.; Kung C.; Van Wijk R.; AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica 2020,106(1),238-249